Journal
BLOOD
Volume 100, Issue 12, Pages 4169-4176Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2002-04-1063
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA-85922, R01 CA-72669] Funding Source: Medline
Ask authors/readers for more resources
Bone marrow (BM)-derived dendritic cells (DCs) cultured in granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (1L-4) have been used to generate antitumor immune responses. The cytokine Flt3 ligand (Flt3L) also has been shown to generate BM DCs. We sought to determine if DCs generated by using Flt3L then matured with lipopolysaccharide (LPS) could lead to DCs with in vivo anti-acute myelogenous leukemia (anti-AML) activity. LIPS and tumor necrosis factor alpha (TNF-alpha) are effective agents for maturing DCs; however, they have potential in vivo toxicities. Cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpGs) are considered relatively nontoxic, potent activators of DC function and maturation in vitro and in vivo. We investigated whether CpGs would be comparable to TNF-alpha or LPS for the maturation of GM-CSF/ IL-4-generated DCs. DCs cultured with GM-CSF/IL-4 and matured with TNF-ct, LIPS, or CpG produced a greater allogeneic T-cell response compared with Flt3L/LPS-generated Ms. All 4 distinct DC types were pulsed with AML-lysate and administered before tumor challenge produced an increase in the total number of splenic anti-AML-specific cytotoxic T-lymphocyte precursors and led to significantly (P less than or equal to .0001) improved survival compared with nonvaccinated controls. GM-CSFAL-4/LPS was superior to Flt3L/LPS for generating anti-AML effects in vivo. Whereas TNF-alpha was comparable to LIPS in conferring on GM-CSFAL-4 DCs anti-AML effects in vivo, CpGs were superior to LIPS. These data have important clinical implications and are the first to show that Flt3L-generated DCs can provide antitumor protection and that nontoxic agents such as CpGs and Flt3L may be useful in the clinical development of DC vaccines. (Blood. 2002; 100:4169-4176). (C) 2002 by The American Society of Hematology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available